Researchers from Exscientia, the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences demonstrated the impact of using Exscientia’s AI-supported precision medicine platform to propose which therapy would be most effective for late-stage hematological cancer patients, based on testing drug responses ex vivo in their own tissue samples.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
